机构：[1]Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, Australia[2]Department of Nephrology, PrincessAlexandra Hospital, Brisbane, Australia[3]Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou,China大德路总院肾内科大德路总院肾内科广东省中医院[4]School of Medicine, The University of Queensland, Queensland, Australia[5]School of Medicine and Pharmacology, Sir CharlesGairdner Hospital Unit, The University of Western Australia, Perth, Australia[6]Department of Nephrology, Prince of Wales Hospital,Sydney, Australia[7]School of Public Health, University of Sydney, Sydney, Australia[8]Department of Nephrology, Monash Health andDepartment of Medicine, Monash University–Melbourne, Melbourne, Australia[9]School of Medicine, University of Adelaide, Adelaide,Australia[10]School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
Patient outcomes in end-stage kidney disease (ESKD) secondary to lupus nephritis have not been well described. To help define this we compared dialysis and transplant outcomes of patients with ESKD due to lupus nephritis to all other causes. All patients diagnosed with ESKD who commenced renal replacement therapy in Australia and New Zealand (1963-2012) were included. Clinical outcomes were evaluated in both a contemporary cohort (1998-2012) and the entire 50-year cohort. Of 64,160 included patients, 744 had lupus nephritis as the primary renal disease. For the contemporary cohort of 425 patients with lupus nephritis, the 5-year dialysis patient survival rate was 69%. Of 176 contemporary patients with lupus nephritis who received their first renal allograft, the 5-year patient, overall renal allograft, and death-censored renal allograft survival rates were 95%, 88%, and 93%, respectively. Patients with lupus nephritis had worse dialysis patient survival (adjusted hazard ratio 1.33, 95% confidence interval 1.12-1.58) and renal transplant patient survival (adjusted hazard ratio 1.87, 95% confidence interval 1.18-2.98), but comparable overall renal allograft survival (adjusted hazard ratio 1.19, 95% confidence interval 0.84-1.68) and death-censored renal allograft survival (adjusted hazard ratio 1.05, 95% confidence interval 0.68-1.62) compared with ESKD controls. Similar results were found in the entire cohort and when using competing-risks analysis. Thus, the ESKD of lupus nephritis was associated with worse dialysis and transplant patient survival but comparable renal allograft survival compared with other causes of ESKD.
基金：
Australian Organ and Tissue Donation and Transplantation Authority; New Zealand Ministry of Health; Kidney Health Australia
第一作者机构：[1]Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, Australia[2]Department of Nephrology, PrincessAlexandra Hospital, Brisbane, Australia[3]Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou,China
通讯作者：
通讯机构：[1]Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, Australia[2]Department of Nephrology, PrincessAlexandra Hospital, Brisbane, Australia[4]School of Medicine, The University of Queensland, Queensland, Australia[*1]Department of Nephrology, Level 2, Ambulatory Renal and Transplant Services Building, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Queensland 4102, Australia
推荐引用方式(GB/T 7714)：
Zhang Lei,Lee Gavin,Liu Xusheng,et al.Long-term outcomes of end-stage kidney disease for patients with lupus nephritis[J].KIDNEY INTERNATIONAL.2016,89(6):1337-1345.doi:10.1016/j.kint.2016.02.014.
APA：
Zhang, Lei,Lee, Gavin,Liu, Xusheng,Pascoe, Elaine M.,Badve, Sunil V....&Johnson, David W..(2016).Long-term outcomes of end-stage kidney disease for patients with lupus nephritis.KIDNEY INTERNATIONAL,89,(6)
MLA：
Zhang, Lei,et al."Long-term outcomes of end-stage kidney disease for patients with lupus nephritis".KIDNEY INTERNATIONAL 89..6(2016):1337-1345
医学